We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER’s Office of Compliance Details Strides COVID-19 Forced It to Make in 2021
CDER’s Office of Compliance Details Strides COVID-19 Forced It to Make in 2021
In 2021, the FDA’s Center for Drug Evaluation and Research (CDER) issued fewer warning letters but conducted moregood clinical practice inspections that the previous year, according to the annual report from CDER’s Office of Compliance (OCC).